>
pdufa.bio

Elranatamab

Updated ยทnext FDA decision on the calendar

Elranatamab is a Roivant/Priovant program. Its next catalyst is a Readout in Dec 2026. Every date links its source.

PFE catalyst hub

All upcoming FDA decision dates on the 2026 PDUFA calendar

About this program

Sponsor: Roivant/Priovant (PFE). We track 1 catalyst event for this program: 1 upcoming and 0 in the record. A PDUFA date is the FDA's target date to complete review of a marketing application; a readout is the sponsor's expected date for clinical trial results. What a PDUFA date is · why we do not compare trial results across drugs.

Catalyst history

Readout · Dec 2026PFE

Questions

When is Elranatamab's next FDA decision or readout?

The next tracked catalyst for Elranatamab is a Readout in Dec 2026.

What happened at Elranatamab's most recent FDA decision?

No FDA decision for Elranatamab is in our archive yet.

Who makes Elranatamab?

Roivant/Priovant (PFE).

Where does this data come from?

FDA announcements, sponsor press releases and SEC filings; every date on this page links its source.